Teva UK launches GoResp Digihaler
The inhaler supports appropriate individuals presenting with asthma and chronic obstructive pulmonary disease
Read More
Tag: Teva
Teva reveals critical Ajovy data
Therapy has been developed to reduce the frequency, duration and severity of migraine attacks
Read More
UK launch for Ajovy injector pen
Teva’s new device allows migraine sufferers to self-administer the drug
Read More
NICE publishes final guidance backing Teva’s Ajovy for migraine
One in seven UK adults is affected by migraine
Read More
Ajovy bags NICE approval
The anti-CGRP preventive therapy is the first of-its-kind to be recommended by NICE.
Read More
Teva undergoes rebranding
The “refreshed visual identity” includes a new digital platform entitled ‘Life Effects’.
Read More
IONTAS, Teva announce new antibody optimisation agreement
Teva recently halted its Ajovy clinical development.
Read More
Teva abandons Ajovy trial for cluster headaches
A Phase III study found that the primary endpoint for weekly average number of cluster headache attacks during the four-week treatment period is unlikely to be met.
Read More
Teva’s anti-CGRP drug Ajovy cleared for migraine prevention
US regulators have approved Teva’s Ajovy for the preventative treatment of migraine in adults.
Read More
Teva drops development of laquinimod
Teva Pharmaceutical Industries has decided not to pursue development of laquinimod, and has returned rights to the drug back to Swedish group Active Biotech.
Read More
Teva, Regeneron’s fasinumab hits osteoarthritis goals
Teva and Regeneron Pharmaceuticals have unveiled positive topline results from a Phase III study assessing the safety and efficacy of fasinumab in patients with chronic pain from osteoarthritis (OA) of the knee or hip.
Read More
Teva pulls fremanezumab cluster headaches trial
Teva is discontinuing a late-stage trial assessing the efficacy of its experimental anti-CGRP therapy fremanezumab in reducing cluster headaches.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
